UMCD6

UMCD6 is a monoclonal antibody targeting the CD6 receptor, a surface glycoprotein primarily expressed on T-lymphocytes and natural killer (NK) cells. Developed at the University of Michigan, UMCD6 functions by disrupting the interaction between CD6 and its ligands, CD166 (ALCAM) and CD318 (CDCP1). Unlike other CD6-targeting antibodies that are primarily investigated for treating autoimmune diseases, UMCD6 has been shown to enhance the activation and cytotoxic potential of NK cells and CD8+ T cells against cancer. It works by up-regulating the NKG2D-DAP10 complex and activating the PI3K pathway, leading to increased tumor infiltration and enhanced killing of cancer cells. Preclinical studies have demonstrated its efficacy in xenograft models of breast and prostate cancer, where it significantly prolonged survival.

Other names

anti-CD6 monoclonal antibodyanti-CD-6 monoclonal antibodyanti-CD 6 monoclonal antibodyanti-human CD6 mAb UMCD6